Asset Details
Do you wish to reserve the book?
Angiopoietin-2 exacerbates cardiac hypoxia and inflammation after myocardial infarction
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Angiopoietin-2 exacerbates cardiac hypoxia and inflammation after myocardial infarction
Do you wish to request the book?
Angiopoietin-2 exacerbates cardiac hypoxia and inflammation after myocardial infarction
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Angiopoietin-2 exacerbates cardiac hypoxia and inflammation after myocardial infarction
2018
Overview
Emerging evidence indicates that angiopoietin-2 (Angpt2), a well-recognized vascular destabilizing factor, is a biomarker of poor outcome in ischemic heart disease. However, its precise role in postischemic cardiovascular remodeling is poorly understood. Here, we show that Angpt2 plays multifaceted roles in the exacerbation of cardiac hypoxia and inflammation after myocardial ischemia. Angpt2 was highly expressed in endothelial cells at the infarct border zone after myocardial infarction (MI) or ischemia/reperfusion injury in mice. In the acute phase of MI, endothelial-derived Angpt2 antagonized Angpt1/Tie2 signaling, which was greatly involved in pericyte detachment, vascular leakage, increased adhesion molecular expression, degradation of the glycocalyx and extracellular matrix, and enhanced neutrophil infiltration and hypoxia in the infarct border area. In the chronic remodeling phase after MI, endothelial- and macrophage-derived Angpt2 continuously promoted abnormal vascular remodeling and proinflammatory macrophage polarization through integrin α5β1 signaling, worsening cardiac hypoxia and inflammation. Accordingly, inhibition of Angpt2 either by gene deletion or using an anti-Angpt2 blocking antibody substantially alleviated these pathological findings and ameliorated postischemic cardiovascular remodeling. Blockade of Angpt2 thus has potential as a therapeutic option for ischemic heart failure.
Publisher
American Society for Clinical Investigation
Subject
/ Angiopoietin-2 - antagonists & inhibitors
/ Animals
/ Antibodies, Blocking - pharmacology
/ Cancer
/ Endothelial Cells - metabolism
/ Endothelial Cells - pathology
/ Hypoxia
/ Ischemia
/ Kinases
/ Male
/ Mice
/ Myocardial Infarction - drug therapy
/ Myocardial Infarction - genetics
/ Myocardial Infarction - metabolism
/ Myocardial Infarction - pathology
/ Receptor, TIE-2 - metabolism
/ Receptors, Vitronectin - genetics
/ Receptors, Vitronectin - metabolism
/ Sepsis
/ Vascular endothelial growth factor
We currently cannot retrieve any items related to this title. Kindly check back at a later time.